The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
Open Access
- 10 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Neurology
- Vol. 11 (1), 144
- https://doi.org/10.1186/1471-2377-11-144
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyThe Lancet Neurology, 2009
- Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.2008
- Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis.2005
- Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosisMultiple Sclerosis Journal, 2005
- Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patternsMultiple Sclerosis Journal, 2005
- A post-marketing study on interferon 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patientsJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Interrupted therapyNeurology, 2003
- Randomized, comparative study of interferon β-1a treatment regimens in MSNeurology, 2002
- Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)The Lancet, 2002